Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.

Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, Facon T, Leleu X, Karlin L, Perrot A, Moreau P, Marit G, Stoppa AM, Royer B, Chaleteix C, Tiab M, Araujo C, Lenain P, Macro M, Voog E, Benboubker L, Allangba O, Jourdan E, Orsini-Piocelle F, Brechignac S, Eveillard JR, Belhadj K, Wetterwald M, Pegourie B, Jaccard A, Eisenmann JC, Glaisner S, Mohty M, Hulin C, Loiseau HA, Mathiot C, Attal M.

Blood. 2018 Dec 13;132(24):2555-2563. doi: 10.1182/blood-2018-07-863829. Epub 2018 Oct 3.

PMID:
30282798
2.

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

Fouquet G, Karlin L, Macro M, Caillot D, Roussel M, Arnulf B, Pegourie B, Petillon MO, Mathiot C, Hulin C, Kolb B, Stoppa AM, Brechiniac S, Rodon P, Dib M, Tiab M, Richez V, Araujo C, Wetterwald M, Garderet L, Royer B, Perrot A, Benboubker L, Decaux O, Escoffre-Barbe M, Fermand JP, Moreau P, Avet-Loiseau H, Attal M, Facon T, Leleu X.

Ann Hematol. 2018 May;97(5):831-837. doi: 10.1007/s00277-018-3236-6. Epub 2018 Jan 12.

PMID:
29330561
3.

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP.

J Clin Oncol. 2016 Jun 20;34(18):2125-32. doi: 10.1200/JCO.2015.63.1929. Epub 2016 Apr 25.

PMID:
27114594
4.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoffre M, Stoppa AM, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JC, Allangba O, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand JP, Rodon P, Kolb B, Glaisner S, Malfuson JV, Lenain P, Biron L, Planche L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M.

Blood. 2016 May 26;127(21):2569-74. doi: 10.1182/blood-2016-01-693580. Epub 2016 Mar 21.

5.

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

Fouquet G, Pegourie B, Macro M, Petillon MO, Karlin L, Caillot D, Roussel M, Arnulf B, Mathiot C, Marit G, Kolb B, Stoppa AM, Brechiniac S, Richez V, Rodon P, Banos A, Wetterwald M, Garderet L, Royer B, Hulin C, Benbouker L, Decaux O, Escoffre-Barbe M, Fermand JP, Attal M, Avet-Loiseau H, Moreau P, Facon T, Leleu X; IFM (Intergroupe Francophone du Myélome).

Ann Oncol. 2016 May;27(5):902-7. doi: 10.1093/annonc/mdw017. Epub 2016 Jan 19.

6.

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome (IFM).

Blood. 2015 Feb 26;125(9):1411-7. doi: 10.1182/blood-2014-11-612069. Epub 2015 Jan 9.

7.

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.

Chretien ML, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, Karlin L, Roussel M, Stoppa AM, Guilhot F, Lamy T, Garderet L, Pegourie B, Dib M, Sebban C, Lenain P, Brechignac S, Royer B, Wetterwald M, Legros L, Orsini-Piocelle F, Voillat L, Delbrel X, Caillot D, Macro M, Facon T, Attal M, Moreau P, Avet-Loiseau H, Corre J.

Haematologica. 2014 Jul;99(7):1236-8. doi: 10.3324/haematol.2013.098608. Epub 2014 Apr 11.

8.

The translocation t(4;14) can be present only in minor subclones in multiple myeloma.

Hébraud B, Caillot D, Corre J, Marit G, Hulin C, Leleu X, Lodé L, Wetterwald M, Dib M, Rodon P, Voillat L, Royer B, Voog E, Fitoussi O, Stoppa AM, Garderet L, Kolb B, Maigre M, Boullanger N, Allangba O, Karlin L, Daguindau N, Legros L, Sohn C, Joubert MV, Lenain P, Facon T, Attal M, Moreau P, Avet-Loiseau H.

Clin Cancer Res. 2013 Sep 1;19(17):4634-7. doi: 10.1158/1078-0432.CCR-12-3866. Epub 2013 Jul 15.

9.

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M, Royer B, Dib M, Voillat L, Bouscary D, Caillot D, Wetterwald M, Pegourie B, Lepeu G, Corront B, Karlin L, Stoppa AM, Fuzibet JG, Delbrel X, Guilhot F, Kolb B, Decaux O, Lamy T, Garderet L, Allangba O, Lifermann F, Anglaret B, Moreau P, Harousseau JL, Facon T.

J Clin Oncol. 2013 Aug 1;31(22):2806-9. doi: 10.1200/JCO.2012.46.2598. Epub 2013 Jun 24.

10.

Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients.

Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dereure O, Wetterwald M, d'Incan M, Grange F, Cornillon J, Tertian G, Maubec E, Saiag P, Barete S, Templier I, Aubin F, Dalle S.

Br J Dermatol. 2013 Sep;169(3):579-86. doi: 10.1111/bjd.12412.

PMID:
23646868
11.

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.

Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld P.

Haematologica. 2013 Jan;98(1):87-94. doi: 10.3324/haematol.2012.067058. Epub 2012 Aug 8.

12.

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, Stoppa AM, Voillat L, Wetterwald M, Pegourie B, Voog E, Tiab M, Banos A, Jaubert J, Bouscary D, Macro M, Kolb B, Traulle C, Mathiot C, Magrangeas F, Minvielle S, Facon T, Moreau P.

J Clin Oncol. 2012 Jun 1;30(16):1949-52. doi: 10.1200/JCO.2011.36.5726. Epub 2012 Apr 30.

PMID:
22547600
13.

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pégourié B, Kolb B, Stoppa AM, Fuzibet JG, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traullé C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau JL.

Blood. 2011 Nov 24;118(22):5752-8; quiz 5982. doi: 10.1182/blood-2011-05-355081. Epub 2011 Aug 17.

14.

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat L, Mathiot C, Kolb B, Macro M, Campion L, Wetterwald M, Stoppa AM, Hulin C, Facon T, Attal M, Minvielle S, Harousseau JL.

J Clin Oncol. 2010 Oct 20;28(30):4630-4. doi: 10.1200/JCO.2010.28.3945. Epub 2010 Jul 19.

PMID:
20644101
15.

Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?

Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dompmartin A, d'Incan M, Maubec E, Grange F, Dereure O, Prey S, Barete S, Wetterwald M, Fraitag S, Petrella T.

Br J Dermatol. 2010 Jan;162(1):74-9. doi: 10.1111/j.1365-2133.2009.09373.x. Epub 2009 Jun 22.

PMID:
19689477
16.

Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.

Moreau P, Attal M, Garban F, Hulin C, Facon T, Marit G, Michallet M, Doyen C, Leyvraz S, Mohty M, Wetterwald M, Mathiot C, Caillot D, Berthou C, Benboubker L, Garderet L, Chaleteix C, Traullé C, Fuzibet JG, Jaubert J, Lamy T, Casassus P, Dib M, Kolb B, Dorvaux V, Grosbois B, Yakoub-Agha I, Harousseau JL, Avet-Loiseau H; SAKK; IFM Group.

Leukemia. 2007 Sep;21(9):2020-4. Epub 2007 Jul 12.

PMID:
17625611
17.

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau JL, Facon T, Mathiot C.

Blood. 2007 Apr 15;109(8):3489-95. Epub 2007 Jan 5.

18.

[Avascular osteonecrosis of the jaws induced by diphosphonates].

Lannoy D, Decaudin B, Barrier F, Bemba M, Wierre L, Pignon JM, Horrent S, Résibois JP, Wetterwald M, Odou P.

Therapie. 2006 Jul-Aug;61(4):363-5. French. No abstract available.

PMID:
17124954
19.

Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma.

Morschhauser F, Depil S, Jourdan E, Wetterwald M, Bouabdallah R, Marit G, Solal-Céligny P, Sebban C, Coiffier B, Chouaki N, Bauters F, Dumontet C.

Ann Oncol. 2007 Feb;18(2):370-5. Epub 2006 Oct 30.

PMID:
17074972
20.

Gemtuzumab ozogamicin-induced sinusoidal obstructive syndrome treated with defibrotide: a case report.

Lannoy D, Decaudin B, Grozieux de Laguérenne A, Barrier F, Pignon JM, Wetterwald M, Odou P.

J Clin Pharm Ther. 2006 Aug;31(4):389-92.

PMID:
16882110
21.

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.

Facon T, Mary JY, Pégourie B, Attal M, Renaud M, Sadoun A, Voillat L, Dorvaux V, Hulin C, Lepeu G, Harousseau JL, Eschard JP, Ferrant A, Blanc M, Maloisel F, Orfeuvre H, Rossi JF, Azaïs I, Monconduit M, Collet P, Anglaret B, Yakoub-Agha I, Wetterwald M, Eghbali H, Vekemans MC, Maisonneuve H, Troncy J, Grosbois B, Doyen C, Thyss A, Jaubert J, Casassus P, Thielemans B, Bataille R; Intergroupe Francophone du Myélome (IFM) group.

Blood. 2006 Feb 15;107(4):1292-8. Epub 2005 Sep 20.

22.

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.

Pecherstorfer M, Steinhauer EU, Rizzoli R, Wetterwald M, Bergström B.

Support Care Cancer. 2003 Aug;11(8):539-47. Epub 2003 Jun 3.

PMID:
12783289
23.

Karyotypic abnormalities in myelofibrosis following polycythemia vera.

Andrieux J, Demory JL, Caulier MT, Agape P, Wetterwald M, Bauters F, Laï JL.

Cancer Genet Cytogenet. 2003 Jan 15;140(2):118-23.

PMID:
12645649
24.

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.

Menssen HD, Sakalová A, Fontana A, Herrmann Z, Boewer C, Facon T, Lichinitser MR, Singer CR, Euller-Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Thiel E, Delmas PD.

J Clin Oncol. 2002 May 1;20(9):2353-9.

PMID:
11981007
25.

Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.

Millot F, Brice P, Philippe N, Thyss A, Demeoq F, Wetterwald M, Boccara JF, Vilque JP, Guyotat D, Guilhot J, Guilhot F.

J Pediatr Hematol Oncol. 2002 Jan;24(1):18-22.

PMID:
11902732
26.

p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders?

Roumier C, Daudignon A, Soenen V, Dupriez B, Wetterwald M, Lai JL, Cosson A, Fenaux P, Preudhomme C.

Haematologica. 1999 Dec;84(12):1075-80.

27.

Four cases of follicular lymphoma with t(14;18)(q32;q21) and t(3;4)(q27;p13) with LAZ3 (BCL6) rearrangement.

Daudignon A, Bisiau H, Le Baron F, Laï JL, Wetterwald M, Galiègue-Zouitina S, Morel P, Duthilleul P.

Cancer Genet Cytogenet. 1999 Jun;111(2):157-60.

PMID:
10347555
28.

VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).

Mineur P, Ménard JF, Le Loët X, Bernard JF, Grosbois B, Pollet JP, Azais I, Laporte JP, Doyen C, De Gramont A, Wetterwald M, Euller-Ziegler L, Peny AM, Monconduit M, Michaux JL.

Br J Haematol. 1998 Nov;103(2):512-7.

PMID:
9827927
30.

Frequency of molecular elimination of Ph1 clone in chronic myelogenous leukemia (CML) with interferon alpha.

Henic N, Preudhomme C, Noel M, Lai J, Wetterwald M, Simon M, Fenaux P.

Leukemia. 1996 Jan;10(1):185-6. No abstract available.

PMID:
8558928
31.

[Idiopathic antehypophyseal insufficiency in the elderly: apropos of 6 cases].

Verlet E, Houque D, Stevenard C, Wetterwald M, Delbecque H.

Rev Med Interne. 1993;14(10):965. French.

PMID:
8009061

Supplemental Content

Loading ...
Support Center